All In Biotech

NDA 201292 · Boehringer Ingelheim

Gilotrif

Afatinib Dimaleate · Oral · Kinase Inhibitor

NovelPriority reviewOrphan

Last checked: Nov 19, 2026Latest source record: Apr 7, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2013

Jul 12, 2013

Approved uses

5

Original approval plus efficacy supplements

Registered trials

209

22 Phase 3, 13 recruiting

FAERS reports

6,622

5,732 serious, 1,475 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 13, 2025.

GILOTRIF is a kinase inhibitor indicated for: First-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test ( 1.1 ) Limitations of Use : Safety and efficacy of GILOTRIF were not established in patients whose tumors have resistant EGFR mutations ( 1.1 ) Treatment of patients with metastatic, squamous NSCLC progressing after platinum-based chemotherapy ( 1.2 ) 1.1 EGFR Mutation-Positive, Metastatic Non-Small Cell Lung Cancer GILOTRIF is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test [see Dosage and Administration (2.1) , Clinical Pharmacology (12.1) , Clinical Studies (14.1) ]. Limitations of Use : The safety and efficacy of GILOTRIF have not been established in patients whose tumors have resistant EGFR mutations [see Clinical Studies (14.1) ]. 1.2 Previously Treated, Metastatic Squamous NSCLC GILOTRIF is indicated for the treatment of patients with metastatic squamous NSCLC progressing after platinum-based chemotherapy .

Mechanism: Afatinib covalently binds to the kinase domains of EGFR (ErbB1), HER2 (ErbB2), and HER4 (ErbB4) and irreversibly inhibits tyrosine kinase autophosphorylation, resulting in downregulation of ErbB signaling. Certain mutations in EGFR, including non-resistant mutations in its kinase domain, can result in increased autophosphorylation of the receptor, leading to receptor activation, sometimes in the absence of ligand binding, and can support cell proliferation in NSCLC. Non-resistant mutations are defined as those occurring in exons constituting the kinase domain of EGFR that lead to increased...

Therapeutic areas: Oncology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 7, 2022 Supplement 17 · Efficacy · priority review OrphanLetterLabel
  • Jan 12, 2018 Supplement 14 · Efficacy · priority review OrphanLabelLetter
  • Apr 15, 2016 Supplement 7 · Efficacy LabelLetter
  • Nov 9, 2015 Supplement 6 · Efficacy OrphanLetterLabel
  • Jul 12, 2013 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanReviewSummary ReviewLetter
3 products under this application
  • GILOTRIF · AFATINIB DIMALEATE EQ 30MG BASE · TABLET, ORAL · Prescription · TE AB
  • GILOTRIF · AFATINIB DIMALEATE EQ 40MG BASE · TABLET, ORAL · Prescription · TE AB
  • GILOTRIF · AFATINIB DIMALEATE EQ 20MG BASE · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Afatinib Dimaleate" as an intervention, any sponsor and status, largest first.

All 209 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • diarrhoea2,128
  • malignant neoplasm progression1,696
  • rash884
  • death524
  • nausea488
  • stomatitis486
  • decreased appetite450
  • vomiting410
  • paronychia355
  • dehydration317
  • fatigue292
  • off label use283

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20125
2013122
2014503
2015744
2016794
2017731
2018936
2019645
2020582
2021456
2022343
2023283
2024214
2025161
2026103

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Gilotrif (Afatinib Dimaleate)

2024 spending

$61.1M

Beneficiaries

940

5,410 claims

Per beneficiary

$65,026

$377.50 per unit

View as table
YearSpending
2020$44,968,931
2021$41,065,614
2022$44,799,472
2023$51,441,559
2024$61,124,499

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 5 on PubMed

Sponsor: Boehringer Ingelheim

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.